193 related articles for article (PubMed ID: 31487676)
1. PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment.
Chen JA; Esteghamat N; Kim EJ; Garcia G; Gong J; Fakih MG; Bold RJ; Cho MT
J Natl Compr Canc Netw; 2019 Sep; 17(9):1026-1030. PubMed ID: 31487676
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.
Mehrvarz Sarshekeh A; Overman MJ; Kopetz S
Future Oncol; 2018 Aug; 14(18):1869-1874. PubMed ID: 29473436
[TBL] [Abstract][Full Text] [Related]
3. Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors.
Sobecki-Rausch J; Barroilhet L
Curr Treat Options Oncol; 2019 Nov; 20(11):83. PubMed ID: 31754884
[TBL] [Abstract][Full Text] [Related]
4. Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Ghiringhelli F; Fumet JD
Front Immunol; 2019; 10():1816. PubMed ID: 31447840
[TBL] [Abstract][Full Text] [Related]
5. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P; Li L; Jiang X; Li Q
J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
Gong J; Robertson MD; Kim E; Fakih M; Schrock AB; Tam KW; Burugapalli B; Monjazeb AM; Hendifar AE; Hitchins M; Klempner SJ; Cho M
Clin Colorectal Cancer; 2019 Dec; 18(4):307-309. PubMed ID: 31563511
[No Abstract] [Full Text] [Related]
7. Immunotherapy of Colon Cancer.
Stein A; Folprecht G
Oncol Res Treat; 2018; 41(5):282-285. PubMed ID: 29705788
[TBL] [Abstract][Full Text] [Related]
8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
9. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
Lee V; Murphy A; Le DT; Diaz LA
Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
[TBL] [Abstract][Full Text] [Related]
10. Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system.
Hirsch D; Gaiser T; Merx K; Weingaertner S; Forster M; Hendricks A; Woenckhaus M; Schubert T; Hofheinz RD; Gencer D
J Cancer Res Clin Oncol; 2021 Jan; 147(1):263-273. PubMed ID: 32776177
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches.
Tintelnot J; Stein A
World J Gastroenterol; 2019 Aug; 25(29):3920-3928. PubMed ID: 31413527
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
13. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
[TBL] [Abstract][Full Text] [Related]
14. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
Overman MJ; Ernstoff MS; Morse MA
Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
[TBL] [Abstract][Full Text] [Related]
15. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
16. A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease Receiving Steroid Therapy.
Massucci M; Di Fabio F; Rojas Llimpe FL; Ardizzoni A
J Immunother; 2020 Jun; 43(5):153-155. PubMed ID: 31913208
[TBL] [Abstract][Full Text] [Related]
17. Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
Llosa NJ; Luber B; Siegel N; Awan AH; Oke T; Zhu Q; Bartlett BR; Aulakh LK; Thompson ED; Jaffee EM; Durham JN; Sears CL; Le DT; Diaz LA; Pardoll DM; Wang H; Housseau F; Anders RA
Cancer Immunol Res; 2019 Oct; 7(10):1574-1579. PubMed ID: 31439614
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
19. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
20. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
